

Special Issue

Personalized Medicine in Skull Base and Sinonasal Tumors

Message from the Guest Editors

In recent decades, multidisciplinary approaches and innovations in treatments (such as endoscopic surgery and heavy ion irradiation) have improved outcomes in sinonasal and skull base tumors. However, a relevant proportion of patients still bears a poor prognosis despite the intensified regimen of treatment. Tumor biology largely drives prognosis in this subset of patients, while the rarity of these tumors, together with their great histologic variety, hinders a more accurate definition of tumor profiles. Multi-omics analysis could largely improve our understanding of these diseases and provide us with biomarkers to better depict these tumors at multiple levels: diagnosis, prognostic stratification, and the prediction of response to treatment. Likewise, they can identify therapeutic targets to inspire new pharmaceutical options. In this regard, the tumor–host interplay, immune contexture, and immunotherapy are still to be investigated in sinonasal and skull base tumors, representing a new therapeutic frontier to explore. Overall, such studies can possibly pave the way towards a more effective, less toxic, personalized therapy.

Guest Editors

Dr. Davide Mattavelli

Unit of Otorhinolaryngology—Head and Neck Surgery, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy

Dr. Paolo Bossi

Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy

Deadline for manuscript submissions

closed (5 March 2024)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/133958

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).